Innate Pharma: Change at the topCo-founder of immuno-oncology start-up Innate Pharma Hervé Brailly is making room on the chair of the executive board. His successor Mondher Majhoubi transfers from AstraZeneca, where he was Senior … more ➔
uniQure: From interim to permanentGene therapy company uniQure NV has named Matthew Kapusta its new Chief Executive Officer. Kapusta has been interim CEO since September and also served as Chief Financial Officer for the last two ye … more ➔
BASF: Crew change in health and nutritionAmong other appointments, BASF has named Melanie Maas-Brunner as new President Nutrition and Health, effective April 1, 2017. Previously, Maas-Brunner held the position of Senior Vice President Performance … more ➔
Confo Therapeutics: High calibre chairDrug discovery company Confo Therapeutics has appointed John Edward Berriman as non-executive director and chairman of the board of directors. Berriman is set to take his seat on the board December 21. more ➔
F2G: Medical referenceAntifungal drug developer F2G Ltd has appointed distinguished research scientist John Rex to the position of Chief Medical Officer. more ➔
Merck: Strategic hikeAt the beginning of October, Isabel De Paoli assumed the position of Chief Strategy Officer at German healthcare company Merck GmbH. She will head the Group Strategy and Transformation Function, which … more ➔
Pharmalink: Gaining momentumIn order to prepare for the start of Phase III trials with its lead drug candidate Nefecon, Pharmalink AB has made several new appointments. Among them Kari Sandvold, who will take over as Vice President … more ➔
Symphogen: Big shoes to fillCopenhagen-based Symphogen is losing its long-time CEO Kirsten Drejer, who co-founded the Danish antibody specialist in 2000. In her place, erstwhile CFO Martin Olin is taking over the helm. more ➔
Enterprise Therapeutics: Vital serviceEpidarex Capital-backed respiratory disease start-up Enterprise Therapeutics has named biotech entrepreneur John Ford as its new CEO. Ford previously co-founded Xention, Ario Pharma, and Metrion Biosciences. more ➔
Confo Therapeutics: Time for changeConfo Therapeutics wants to metamorphose from a tech company to a drug discovery company, and it has hired Cedric Ververken to guide the transition. more ➔
